Massachusetts Financial Services Co. MA Sells 75,634 Shares of BioAtla, Inc. (NASDAQ:BCAB)

Massachusetts Financial Services Co. MA trimmed its position in shares of BioAtla, Inc. (NASDAQ:BCAB) by 15.1% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 424,237 shares of the company’s stock after selling 75,634 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in BioAtla were worth $21,568,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. JPMorgan Chase & Co. bought a new stake in BioAtla during the fourth quarter worth about $37,000. UBS Group AG grew its stake in BioAtla by 399.6% during the first quarter. UBS Group AG now owns 2,528 shares of the company’s stock worth $129,000 after buying an additional 2,022 shares during the last quarter. Strs Ohio bought a new stake in shares of BioAtla during the first quarter valued at approximately $142,000. Teachers Retirement System of The State of Kentucky bought a new stake in shares of BioAtla during the fourth quarter valued at approximately $102,000. Finally, Alliancebernstein L.P. bought a new stake in shares of BioAtla during the first quarter valued at approximately $224,000. 56.45% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ BCAB opened at $41.11 on Friday. The firm has a 50 day simple moving average of $44.71. BioAtla, Inc. has a fifty-two week low of $27.15 and a fifty-two week high of $76.63.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings data on Tuesday, May 11th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.04). Equities analysts predict that BioAtla, Inc. will post -1.86 EPS for the current fiscal year.

Several research firms have recently commented on BCAB. BTIG Research increased their price target on shares of BioAtla from $47.00 to $87.00 and gave the company a “buy” rating in a research note on Friday, March 26th. JPMorgan Chase & Co. increased their price target on shares of BioAtla from $45.00 to $64.00 and gave the company an “overweight” rating in a research note on Tuesday, May 4th.

In other BioAtla news, CEO Jay M. Phd Short sold 55,000 shares of the stock in a transaction on Monday, June 21st. The shares were sold at an average price of $39.13, for a total value of $2,152,150.00. Following the sale, the chief executive officer now directly owns 1,441,508 shares in the company, valued at $56,406,208.04. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jay M. Phd Short sold 19,269 shares of the stock in a transaction on Thursday, June 17th. The stock was sold at an average price of $39.22, for a total transaction of $755,730.18. Following the completion of the sale, the chief executive officer now owns 1,441,508 shares in the company, valued at $56,535,943.76. The disclosure for this sale can be found here. Corporate insiders own 35.50% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc, a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types.

Recommended Story: Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding BCAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioAtla, Inc. (NASDAQ:BCAB).

Institutional Ownership by Quarter for BioAtla (NASDAQ:BCAB)

Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.